$0.40
0.00 (-0.77%)
Open$0.31
Previous Close$0.40
Day High$0.43
Day Low$0.25
52W High$1.51
52W Low$0.30
Volume—
Avg Volume152.3K
Market Cap3.86M
P/E Ratio—
EPS$-1.90
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+6,849.9% upside
Current
$0.40
$0.40
Target
$27.73
$27.73
$20.43
$27.73 avg
$35.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.57M | 1.60M | 1.25M |
| Net Income | 4.2K | 5.8K | 3.4K |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| EBITDA | 8.2K | 8.5K | 6.5K |
| Free Cash Flow | 4.7K | 4.2K | 2.8K |
| Rev Growth | -8.5% | +15.0% | -6.0% |
| Debt/Equity | 0.92 | 0.88 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |